# Comparative Formulation Study of Vabicaserin

> **NCT00928551** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 15 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** vabicaserin

## Key facts

- **NCT ID:** NCT00928551
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2009-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928551, "Comparative Formulation Study of Vabicaserin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00928551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*